Sight Sciences Earnings Call Highlights Disciplined Growth

Sight Sciences, Inc. ((SGHT)) has held its Q4 earnings call. Read on for the main highlights of the call.

Sight Sciences’ latest earnings call balanced cautious optimism with clear evidence of operational progress. Management highlighted modest top-line growth, industry-leading margins, and sharply lower losses while celebrating a key reimbursement win that should unlock its TearCare dry eye platform. At the same time, they stressed that growth still hinges on payer expansion, commercial execution, and navigating future reimbursement changes.

Total Revenue Growth Shows Early Diversification

Sight Sciences reported Q4 revenue of $20.4 million, a 7% year-over-year increase, powered mainly by its Interventional Glaucoma franchise and early contributions from Interventional Dry Eye. The mix shows glaucoma still dominates the business, but dry eye is starting to register in the numbers and offers a second leg of growth if adoption scales.

Interventional Glaucoma Holds Ground Amid Market Noise

Interventional Glaucoma revenue reached $19.7 million in Q4, up 5% from a year earlier and flat sequentially as the company worked through market and reimbursement headwinds. Account ordering grew about 2%, and higher Omni Edge usage supported healthy utilization and higher average selling prices, indicating underlying procedure demand remains resilient.

TearCare Reimbursement Milestone Fuels Dry Eye Ambition

Interventional Dry Eye revenue jumped to $0.7 million in Q4 from $0.3 million a year ago, reflecting early traction for the TearCare system. A major catalyst arrived as two Medicare Administrative Contractors set pricing for CPT 0563T, enabling a reimbursed business model, with Q4 volumes of roughly 700 SmartLids sold to about 80 accounts, including around 30 new sites.

Very Strong Gross Margins Underpin Earnings Power

Company-wide gross margin held at a robust 87% in Q4, underscoring the high-value nature of its ophthalmic technology. Interventional Glaucoma margins improved to 88%, while Interventional Dry Eye climbed to 68% from 51% thanks to better pricing and mix, giving the company significant leverage as volumes grow.

Cost Discipline Sharpens and Losses Narrow

Total operating expenses fell 25% year-over-year to $21.5 million, with adjusted operating expenses down 23% to $18.9 million after an August workforce reduction. The tighter cost base translated into a much smaller net loss of $4.2 million, or $0.08 per share, versus $11.8 million, or $0.23, a year earlier.

Cash Management Supports Path Toward Breakeven

Sight Sciences ended Q4 with $92 million of cash and equivalents, down from $120.4 million a year earlier but reflecting very modest Q4 cash usage of only $0.4 million. Management pointed to this minimal burn as evidence that the company can move toward cash flow breakeven without turning to additional equity financing, assuming execution stays on track.

2026 Revenue Guidance Targets Balanced Growth

For 2026, management guided to revenue of $82 million to $88 million, implying 6% to 14% growth over 2025. The outlook assumes Interventional Glaucoma contributes $77 million to $81 million, or 2% to 7% growth, while Interventional Dry Eye expands to $5 million to $7 million from $1.6 million, driven by a ramp in reimbursed TearCare procedures.

Targeted Investments Aim to Scale Both Franchises

The company plans to increase adjusted operating expenses to $93 million to $96 million in 2026, up 6% to 9%, focused on market access and commercial build-out. Spending will concentrate on scaling reimbursed Interventional Dry Eye and better penetrating the stand-alone Interventional Glaucoma market, with management emphasizing continued financial discipline despite the investment uptick.

Dry Eye Opportunity Remains Early and Constrained

Despite strong percentage growth, Interventional Dry Eye is still a small business at $0.7 million in Q4, reflecting limited sales infrastructure and patchy payer coverage. Management’s 2026 guidance assumes no additional Medicare coverage wins, signaling that upside is possible but not yet baked into the forecast and that adoption will scale gradually.

Cash Decline and Debt Temper Financial Flexibility

The year-over-year cash decline from $120.4 million to $92 million highlights the cost of building out two platforms in a pressured medtech environment. With $40 million of debt on the balance sheet, the company’s financial flexibility is more constrained, making ongoing operating discipline and progressing toward breakeven increasingly important for equity holders.

GAAP Profitability Still Out of Reach

Even with marked improvement, Sight Sciences remains loss-making on a GAAP basis, posting a $4.2 million net loss in Q4. Investors will watch whether the combination of high gross margins, controlled OpEx growth, and incremental revenue from dry eye can eventually flip the business into sustained profitability over the next few years.

Guidance Hinges on Execution and Market Access Wins

Management stressed that the 2026 outlook does not rely on additional Medicare or commercial coverage expansions for TearCare, framing guidance as prudent. Any upside will require securing more payer wins and scaling the salesforce effectively, particularly in dry eye, while continuing to defend and grow the glaucoma franchise in a shifting reimbursement landscape.

Glaucoma Reimbursement Changes Create Longer-Term Risk

One key risk flagged was the American Medical Association’s planned code changes for goniotomy procedures, expected to take effect in 2028 and potentially lowering reimbursement. Such revaluation could dampen utilization of related glaucoma procedures and create future growth headwinds, even as the company works to broaden its addressable market.

2025 LCD and Seasonal Factors Weigh on Near-Term Trends

The company is still digesting 2025 local coverage determination changes that restrict multiple mixed procedures with cataract surgery, which hurt device usage and slowed market growth. Management also flagged typical first-quarter seasonality and storm-related disruptions early in 2026, guiding to only low single-digit Q1 glaucoma growth and signaling a back-half-weighted year.

Forward-Looking Guidance Paints a Gradual Ramp

Looking ahead, Sight Sciences expects Q1 to be the weakest quarter, with Interventional Glaucoma growing in the low single digits and Interventional Dry Eye contributing about $1 million. The company anticipates stronger performance in the second half of 2026, underpinned by expanding TearCare utilization, targeted commercial investments, and continued leverage from high gross margins and a leaner cost structure.

Sight Sciences’ earnings call presented a story of improving fundamentals, disciplined spending, and methodical expansion into a new reimbursed dry eye market. While reimbursement changes, debt, and persistent GAAP losses remain risks, management’s conservative guidance and strong margin profile give investors a clearer line of sight to sustainable growth if execution on market access and scaling stays on course.